Authum Investment & Infrastructure Limited has informed the Exchange about Agreements

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

AIIL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.9%Reaction day

₹602.00

prior close

₹616.30

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.5%+6.3% vs market

Non Banking Financial Company (NBFC) peers, median of 194sector-1.0%+5.9% vs sector

On the reaction day the stock moved 6.3 pts more than Nifty Midcap 150 and 5.9 pts more than its Non Banking Financial Company (NBFC) peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.4

15m

-0.2

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.9-1.5+6.3-1.0+5.9

Next day

+6.2-2.6+8.8-2.0+8.2

+7.1-3.2+10.3-1.9+9.0

+6.3-1.5+7.8-1.6+7.9

+5.1-1.3+6.5-1.2+6.4

+5.1-0.7+5.8-1.0+6.1

+2.3-1.2+3.5-1.1+3.4

15d

+8.6+1.9+6.7-0.9+9.5

-1.3-2.2+0.8-2.6+1.2

+1.8+3.0-1.1-1.5+3.4

-10.7+4.6-15.3-4.3-6.4

UpDownMarket · Nifty Midcap 150Sector · Non Banking Financial Company (NBFC) peers, median of 194Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Authum Investment & Infrastructure Limited (AIIL) has signed a Share Subscription cum Purchase Agreement (SSPA) with Rivaara Labs Private Limited and its promoter to acquire a 35.09% stake in the diagnostics company. The total deal value is Rs. 36.57 crore, comprising Rs. 36 crore as primary infusion into 3.6 crore compulsorily convertible preference shares (CCPS) and Rs. 56.83 lakh for purchasing existing equity shares and CCPS from current shareholders. Rivaara Labs operates in the diagnostics space (pathology, imaging, PCR testing, genomic sequencing, RT-PCR kits, and digital healthcare) with FY25 turnover of Rs. 25.53 crore and negative net worth of Rs. 34.83 crore. The transaction is expected to close by September 30, 2025, is a cash deal, and is not a related-party transaction.

Likely market impact

This is a portfolio diversification move into the healthcare diagnostics sector, but the deal size is modest relative to AIIL's scale and the target has declining revenues and negative net worth, so near-term impact on the stock is likely limited. The stake of 35.09% keeps AIIL just below the open-offer threshold, making this a strategic minority investment rather than a control acquisition.